Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 20, 2014
Pharmacy Choice - News - Over-the-Counter Drugs - April 20, 2014

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 23 of 23     Go To Page:

4/19/14 - Innovation, Excellence and Development form Basic Requirement for Pharmaceutical Sector in the Ministry of Health [Emirates News Agency (WAM) (United Arab Emirates)]
Dubai, 19th Apr. 2014- The Ministry of Health gives great concern to the pharmaceutical sector through continuous cooperation between international organizations such as FDA, EMA, WHO and GCC Executive Office in addition to other Australian and international bodies. Amin Al Amiri, Assistant Undersecretary for Medical Practices and Licensing, said:
4/18/14 - Perrigo Announces Launch Of Authorized Generic Version Of Taclonex Ointment Calcipotriene 0.005% / Betamethasone Dipropionate 0.064%
By a News Reporter-Staff News Editor at Health& Medicine Week Perrigo Company plc announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex Ointment. >From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland,
4/17/14 - Actavis to Acquire Four Products from Akorn
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - Actavis to Acquire Four Products from Akorn; Terms Undisclosed
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - BRIEF: Akorn completes $640M acquisition [Chicago Tribune :: ]
April 17 Pharmaceutical company Akorn Inc. said Thursday it completed its acquisition of Hi-Tech Pharmacal Co. Inc. for $640 million in cash. Lake Forest- based Akorn, which focuses mostly on ophthalmology drugs, has said the addition of Amityville, N.Y.- based Hi-Tech will diversify its offerings, adding branded over-the-counter products in the
4/17/14 - Tennessee House OKs bringing back electric chair [Chattanooga Times Free Press, Tenn. :: ]
April 17 NASHVILLE Tennessee would be ready to electrocute death row inmates should lethal injection drugs be unavailable under a bill approved Wednesday by the House. The bill was previously approved by the Senate, but a minor amendment added by the House sends it back to the Senate. Johnny Shaw, R- Bolivar, a pastor, said on the House floor.
4/16/14 - Baxter Announces Primary Efficacy Endpoint for Phase 3 Trial of BAX 11; Cleveland Biolabs Successfuly Close of Phase 1 Study of CBL0102
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 16, 2014.{ nfg} Baxter International Inc. announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111. BAX 111 is a recombinant von Willebrand factor under investigation for the treatmen
4/16/14 - Boehringer Ingelheim pleased with 2013 financial year [Global Data Point]
This resulted in a 2.4 percentage point improvement in the return on net sales to 15 per cent. For the last mentioned indication, the company received marketing approval from the US Food and Drug Administration for PRADAXA at the beginning of April. "We can say that Boehringer Ingelheim came through 2013 well, despite extraordinary effects and
4/16/14 - CTD Holdings, Inc. Closes on Securities Purchase and Collaboration Agreement
CTD Holdings, Inc., a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics and other markets, announced today that it has closed on a Securities Purchase and Collaboration Agreement with Novit LP an affiliated entity of the USP Group, a major manufacturer and distributor of over-the-counter pharmaceutical.
4/16/14 - Johnson %7E Johnson Reports 2014 First-Quarter Results [Global Data Point]
Net earnings and diluted earnings per share for the first quarter of 2014 were $4.7 billion and $1.64, respectively. The first-quarter results included a net gain of after-tax special items of approximately $0.3 billion, related to a tax benefit associated with Conor Medsystems partially offset by integration and transaction costs related to the...
4/16/14 - Johnson & Johnson Reports 2014 First-Quarter Results
Release date- 15042014- New Brunswick, NJ- Johnson& Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013.. The first-quarter results included a net gain of after-tax special items of approximately $0.3 billion, related to a tax benefit associated with Conor Medsys
4/16/14 - NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets
is pleased to announce that it has signed Cross Referencing Agreements for prescription generic products for Canadian markets. NUVA is in the process of securing a Drug Establishment License from Health Canada. Upon receipt of the DEL, NUVA will start filing for regulatory approval of these products with Health Canada.
4/15/14 - Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation
Actavis plc today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess FE. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New
4/15/14 - Actavis Launches Asia Pacific Regional Headquarters in Singapore
By a News Reporter-Staff News Editor at China Weekly News Actavis plc, a leading global specialty pharmaceutical company, announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa region. In addition, Actavis announced that its subsidiary operating in Singa
4/15/14 - HEALTHWAREHOUSE.COM, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operation.
The following discussion of results of operations and financial condition is based upon, and should be read in conjunction with, our consolidated financial statements and accompanying notes thereto, included elsewhere in this Annual Report. This discussion contains forward-looking statements. Actual results could differ materially from the results.
4/15/14 - Johnson & Johnson Reports 2014 First-Quarter Results:
Johnson& Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. The first-quarter results included a net gain of after-tax special items of approximately $0.3 billion, related to a tax
4/15/14 - OXYSURE SYSTEMS INC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis together with the financial statements and the related notes to those statements included in "Item 8- Financial Statements and Supplementary Data." The factors or uncertainties that could cause actual results, performance or achievement to differ materially from forward-looking statements...
4/15/14 - OXYSURE SYSTEMS INC - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis together with the financial statements and the related notes to those statements included in "Item 8- Financial Statements and Supplementary Data." The factors or uncertainties that could cause actual results, performance or achievement to differ materially from forward-looking statements...
4/15/14 - RESTORGENEX CORP - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This report contains forward-looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results,
4/14/14 - Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin
RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014/ PRNewswire/ Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration accepted the filing of the New Drug Application for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type
4/14/14 - Easton Pharmaceuticals Signs "Viorra" Distribution Deal for Mexico
Easton Pharmaceuticals is pleased to announce that BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products have signed an exclusive agreement to distribute Easton's "VIORRA" product in Mexico. Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica, as previously announced, is the company's current r
4/14/14 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 20215) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Nonprescription Drugs Advisory Committee to review new drug application 204804, for over-the-counter marketing of montelukast 10 milligram tablets for the temporary relief of symptoms due to hay fever or other upper respiratory allergies.
4/14/14 - OMICS Group Aims to Apply Vital Responsibility in Pharmaceutical Industry by Regulatory Affairs 2014
Major highlights of this OMICS Group scientific conferences includes current regulatory aspects like API, scheduled drugs, over the counter drugs, subsequent process validation, audit process and inspection, common technical document, NDA and ANDA providing an up to date and in-depth information on the present scenario of the Pharmaceutical regulat
Articles(s): 1 - 23 of 23     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415